English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/123207
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases

AuthorsMartínez, Ana ; Gil, Carmen
KeywordscAMP
PDE4
PDE7
PDE8
PDE inhibitors
Issue Date4-Oct-2014
PublisherTaylor & Francis
CitationExpert Opinion on Therapeutic Patents 24 (12) (2014)
AbstractIntroduction: PDEs are key enzymes in the adenosine and guanosine cyclic nucleotides (cAMP and cGMP) signaling cascade. Their inhibition increases cyclic nucleotide levels inside the cell. Thus, pharmacological modulation of PDE activity can have profound effects on the function of cells and organ systems throughout the body. Areas covered: Among the large PDE families, only PDE4, PDE7 and PDE8 are cAMP-specific hydrolyzing enzymes. cAMP is an important second messenger not only by its involvement in a vast number of physiological processes but also by activation of protein kinase A, exchange protein activated by cAMP (Epac) and cAMP response element-binding (CREB) or cyclic nucleotide-gated channels. Clearly, such enzymes represent ideal drug targets for the pharmacological treatment of many pathologies. The discovery and development of small molecules targeting cAMP-specific PDEs reported in the last 5 years is the focus of the present review. Expert opinion: The first PDE4 inhibitors recently reached the market, having avoided, by different strategies, their dose-limiting side effects (after more than two decades of drug development). Meanwhile, new cAMP-specific PDE7 and PDE8 inhibitors emerged as effective and safe drugs for severe unmet diseases. The therapeutic potential of these inhibitors will be tested in the near future, as many of these drug candidates are ready to start clinical trials.
Description32 p.-5 fig.
Publisher version (URL)http://dx.doi.org/ 10.1517/13543776.2014.968127
URIhttp://hdl.handle.net/10261/123207
DOI10.1517/13543776.2014.968127
ISSN1354-3776
E-ISSN1744-7674
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
EOTP_cAMP-PDE_Revised.docPostprint1,29 MBMicrosoft WordView/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.